Menu Search
Equities

Ekso Bionics Holdings Inc

23E2:MUN

Ekso Bionics Holdings Inc

Actions
  • Price (EUR)0.824
  • Today's Change0.000 / 0.00%
  • Shares traded100.00
  • 1 Year change-37.76%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.

  • Revenue in USD (TTM)17.68m
  • Net income in USD-11.13m
  • Incorporated2012
  • Employees70.00
  • Location
    Ekso Bionics Holdings Inc101 GLACIER POINT, SUITE ASAN RAFAEL 94901United StatesUSA
  • Phone+1 (510) 984-1761
  • Fax+1 (702) 866-2689
  • Websitehttps://ir.eksobionics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.